Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by Sarb99on Dec 27, 2020 2:45pm
430 Views
Post# 32185598

RE:One trick pony - needs viable long term plan

RE:One trick pony - needs viable long term plan

Why would you change your business plan when demand is going up for Covid-19 testing. The testing demand probably stays here for the next couple of years. You can see the image below that shows QuestCap revenue increasing every single day. QuestCap needs to run with this until covid-19 testing demand dies down. 

 

Once Covid-19 testing demand slows down at that point, Medi-vole can add all kinds of in vitro diagnostic testing. By that time, Medi-volve should have a lot of money in the bank account to expand to other services. Just staying in the testing market, in vitro diagnostic testing, the market is over USD 84 Billion and should be around USD 96 billion by 2025. https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html

Then you add Flu shots and Vaccination with the testings. You can increase your revenue even further. 

 

If you watch the last webinar video, you can see Doug saying they will be moving to the other medical service after covid-19 testing slow down. https://www.youtube.com/watch?v=w4aLyWBeZKY&feature=youtu.be

 

Once covid-19 testing demand slows down, Medi-volve should have a client list in millions and 700-1000 testing sites. Any new service Medi-volve wants to offer, all they need is to send an email or SMS to these clients. Medi-volve can add any number of partners or service. Medi-volve can add these services with a good profit margin: 
 

  • in vitro diagnostic testing + flu shots + Vaccination
  • Telehealth + in vitro diagnostic testing + flu shots
  • Mobile medical services + in vitro diagnostic testing + flu shots

 

Here is another possibility, once Covid-19 testing demand slows down. It will affect all other big in vitro diagnostic testing companies like Abbott, Siemens, BD Medical and bioMrieux. What do they need to keep their revenue up? They need to add supply and clients to keep generating revenue that matches previous quarters. Medi-volve can be the best takeover target as they already have millions of clients and 700-1000 testing sites all set up to add all in vitro diagnostic testing services.



rankininlet wrote: I am a bit frustrated by the posters not paying enough addention to what happens to QSC post C-19.  Right now its' growth and margins are sweet, however, at some point in the next few years demand for C-19 expensive testing will implode.  This post is not about guess whening Covid testing disappears, rather it is a flag for the fact that juicy margins & business will disappear and the time to identify a replacement business stream is now.  I ask myself how come the market appears to be underpricing QSC.  Only answer I have is current primary business is temporary with no clear path past C-19 windfalls.  I welcome others to share what comes next ideas.


<< Previous
Bullboard Posts
Next >>